11 Mar The TLC-ART Study
This study will look at drug levels in the blood over time and the safety of a new investigational injectable medication that combines existing short-acting oral drugs used to treat HIV.
Study is approximately 2 months long.
Schedule of Events: Screening Visit, Entry Visit, Visit Days: 1, 2, 3, 7, 10, 14, 21, 28, 35, 49, 57, and 64.
Entry visit is about 9 hours long where the single dose injections will be given.
Reimbursement up to $560 (plus additional $150 lymph node biopsy) = $710 total.
Call/text: 206-773-7129 today!
Participant Eligibility
Healthy adults between ages 18-65
Not taking any prescription medications or over the counter medications
Not currently using hormonal birth control and cannabis.
Contact
Eli Burnham, PA-C
(206) 773-7129
Additional Study Details
Full Study Title
First in Human Clinical Trial of a Next Generation, Long-Acting Injectable combination of Anti-Retroviral Therapy
Investigator(s)
Primary Investigatory: Rachel Bender-Ignacio, MD
Accepts Healthy Volunteers?
Yes
Study Site(s)
UW Positive Research
325 9th AVE
Seattle, Washington 98104
